scholarly journals Campylobacter concisus

2021 ◽  
Vol 15 (09) ◽  
pp. 1216-1221
Author(s):  
Biljana Miljković-Selimović ◽  
Tatjana Babić ◽  
Branislava Kocić ◽  
Ema Aleksić ◽  
Adam Malešević ◽  
...  
Keyword(s):  
Immune Response ◽  
Periodontal Disease ◽  
Inflammatory Bowel Diseases ◽  
Etiological Agent ◽  
Healthy Individuals ◽  
Campylobacter Concisus ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Campylobacter concisus has been described as the etiological agent of periodontal disease, inflammatory bowel diseases, and enterocolitis. It is also detected in healthy individuals. There are differences between strains in healthy individuals and affected ones by production of two exototoxins. In this mini review authors discuss major facts about cultivation, isolation, virulence and immune response to C. concisus.

Factors Affecting Initial Humoral Immune Response to SARS-Cov-2 Vaccines among Patients with Inflammatory Bowel Diseases

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Michael D. Kappelman ◽  
Kimberly N. Weaver ◽  
Xian Zhang ◽  
Xiangfeng Dai ◽  
Runa Watkins ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Inflammatory Bowel Diseases ◽  
Factors Affecting ◽  
Humoral Immune ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Increased serum nesfatin-1 levels in patients with inflammatory bowel diseases

2021 ◽  
pp. postgradmedj-2020-139227
Author(s):  
Şengül Beyaz ◽  
Erdem Akbal
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Inflammatory Diseases ◽  
Inflammatory Marker ◽  
White Cell Count ◽  
Characteristic Curve ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Altered Expression ◽  
Bowel Diseases ◽  
Inflammatory Bowel

BackgroundAdipokines are adipose tissue–derived secreted molecules that can exert anti-inflammatory or proinflammatory activities. Altered expression of adipokines has been described in various inflammatory diseases, including inflammatory bowel diseases (IBDs) such as Crohn’s disease (CD) and ulcerative colitis (UC). Little is known about nesfatin-1, a recently identified adipokine, in IBD. The aim of this study was to investigate serum nesfatin-1 levels in patients with IBD.MethodsThis study included a total of 52 adult individuals (17 patients with CD, 18 patients with UC and 17 healthy volunteers) with similar age and body mass index. Serum nesfatin-1 levels were measured by ELISA in healthy individuals and patients with IBD in their active and remission periods. Blood inflammation markers including C reactive protein (CRP), erythrocyte sedimentation (ESR) and white cell count (WCC) were also measured in patients.ResultsWe found significantly elevated levels of serum nesfatin-1 in the active disease period in both patients with CD (p=0.00003) and patients with UC (p=0.00001), compared with healthy individuals. Serum nesfatin-1 levels moderately decreased in the remission period; however, they were still significantly higher than that of healthy individuals. Receiver operating characteristic curve analyses indicated serum nesfatin-1 with an excellent diagnostic value for IBD. Finally, patients had significantly high CRP, ESR and WCC in the active IBD; however, we found the nesfatin-1 strongly correlated only with ESR in the active CD.ConclusionThis is the first study investigating the circulating levels of nesfatin-1 in patients with IBD. Serum nesfatin-1 may serve as an additional inflammatory marker for diagnosis of IBD in affected individuals.

Probiotics and bowel inflammation

2006 ◽  
Vol 247 ◽  
pp. 1-4
Keyword(s):  
Ulcerative Colitis ◽  
Immune Response ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Safety Issues ◽  
Bowel Diseases ◽  
Inflammatory Bowel

In a nutshellInflammatory bowel diseases can involve problems in the development of the gut's immune response. A healthy bowel flora plays an important role in this development, for example through effects on cytokines.Clinical trials of probiotics for IBD have been predominantly positive for ulcerative colitis and pouchitis, less so for Crohn's disease. So far probiotics appear to be a notably safe therapy, although some theoretical safety issues need to be borne in mind.

scholarly journals Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

2021 ◽  
Author(s):  
Hadar Edelman-Klapper ◽  
Eran Zittan ◽  
Ariella Bar-Gil Shitrit ◽  
Keren Masha Rabinowitz ◽  
Idan Goren ◽  
...  
Keyword(s):  
Immune Response ◽  
Inflammatory Bowel Diseases ◽  
Vaccine Dose ◽  
Drug Levels ◽  
Vaccine Responses ◽  
Tnf Α ◽  
Vaccine Booster ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Administration Timing

Background: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear. Aim: to assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC). Methods: Prospective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike (S) antibodies levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinaly. Results: Overall 258 subjects: 185 IBD (67 treated with anti-TNFα), and 73 HC. After the first vaccine dose all HC were seropositive, while some patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-S levels were significantly lower in anti-TNFα treated compared to untreated patients, and HC (p<0.001; p<0.001, respectively). Neutralizing and inhibitory functions were both lower in anti-TNFα treated compared to untreated patients, and HC (p<0.03; p<0.0001, respectively). Anti-TNFα drug levels and vaccine responses did not affect anti-S levels. Infection rate (~2%) and AEs were comparable in all groups. IBD activity did not change in response to BNT162b2. Conclusions: In this prospective study in patients with IBD stratified according to treatment all patients mounted an immune response to two doses of BNT162b2. However, its magnitude was significantly lower in patients treated with anti-TNFα, regardless of administration timing and drug levels. Vaccine was safe. As vaccine immune response longevity in this group may be limited, vaccine booster dose should be considered.

scholarly journals Impaired Deoxyribonuclease I Activity in Patients with Inflammatory Bowel Diseases

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Karin Malíčková ◽  
Dana Ďuricová ◽  
Martin Bortlík ◽  
Zdenka Hrušková ◽  
Barbora Svobodová ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Diseases ◽  
Blood Donors ◽  
Dnase I ◽  
Healthy Individuals ◽  
Control Groups ◽  
Strong Negative Correlation ◽  
Deoxyribonuclease I ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background and Aims. Deoxyribonuclease I (DNaseI) is an endonuclease that facilitates chromatin breakdown and promotes susceptibility to autoimmune disorders. The aim of current study was to investigate serum DNase I activity in patients with inflammatory bowel diseases (IBD).Patients and Methods. A cohort of 110 IBD patients was evaluated, aged 35±12 years, 77 with Crohn's disease (CD) and 33 with ulcerative colitis (UC). 50 SLE patients and 50 healthy blood donors were examined as control groups.Results. DNase I activity in IBD patients was significantly lower than in healthy individuals, but higher than in SLE patients (P<.0001). Patients with UC showed higher DNase I activity than CD patients,P=.21. DNase I activity in female patients with IBD was significantly lower than in males,P=.024; however, no differences in DNase I activity were found in relation to gender in healthy individuals. DNase I activity has shown a strong negative correlation with the serum concentration of anti-nucleosomal antibodies in the autoimmune (SLE + IBD) cohort, as well as in the separate IBD cohort.Conclusions. Reduced serum DNase I activity probably has pathogenetic consequences in IBD. Induction of autoantibodies towards nucleosomes could be a reflection of impaired DNase I activity.

Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis

Vaccine ◽  
2017 ◽  
Vol 35 (20) ◽  
pp. 2633-2641 ◽  
Author(s):  
Hai-yin Jiang ◽  
Shu-yin Wang ◽  
Min Deng ◽  
Yu-chuan Li ◽  
Zong-xin Ling ◽  
...  
Keyword(s):  
Systematic Review ◽  
Immune Response ◽  
Hepatitis B ◽  
Inflammatory Bowel Diseases ◽  
Meta Analysis ◽  
Hepatitis B Vaccination ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
C. B. Larmonier ◽  
K. W. Shehab ◽  
F. K. Ghishan ◽  
P. R. Kiela
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
System Development ◽  
Bacterial Species ◽  
Immune System Development ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Humans have coevolved with a complex community of bacterial species also referred to as the microbiome, which reciprocally provides critical contributions to human metabolism and immune system development. Gut microbiome composition differs significantly between individuals depending on host genetics, diet, and environmental factors. A dysregulation of the symbiotic nature of the intestinal host-microbial relationship and an aberrant and persistent immune response are the fundamental processes involved in inflammatory bowel diseases (IBD). Considering the essential role of T cells in IBD and the contributing role of the microbiome in shaping the immune response during the pathogenesis of IBD, this review focuses on the complex relationship, interplay, and communication between the gut microbiome and T cells, including their differentiation into different subsets of effector or regulatory cells.

Sign in / Sign up

Export Citation Format

Share Document